Harris D, Casso D, Midkiff K, Anderson A, Gilsenan A, Oliveria A, Andrews E, Kellier-Steele N. Methods, results, and lessons learned from two postmarketing drug safety surveillance studies linking state cancer registry data to large pharmacy databases. Presented at the 2019 NAACCR / IACR Combined Annual Conference; June 11, 2019. Vancouver, Canada.
Harris D, Midkiff K, Gilsenan A, Andrews E. Linking big (federal) data to state cancer registry data for a post-marketing drug safety surveillance study: challenges and lessons learned. Presented at the 2018 Annual Conference of the North American Association of Central Cancer Registries (NAACCR); June 12, 2018. Pittsburgh, PA.
Midkiff KD, Andrews EB, Gilsenan AW, Harris DH. "First in Flight" or "When Pigs Fly" – Can cancer registries play a critical role at the national level in studying cancer as an adverse outcome from drug treatments? Presented at the NAACCR 2015 Annual Conference; June 2015. Charlotte, NC.
Gilsenan AW, Midkiff KD, Andrews EB, Von Scheele BG, Masica D, Ceberg J. Multinational collaboration: a long-term surveillance program for osteosarcoma and potential exposure to teriparatide. Presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.
Harris DH, Gilsenan AW, Midkiff KD, Harding AA. Navigating the registry-specific approval process for a long-term drug safety surveillance study. Presented at the NAACCR - North American Association of Central Cancer Registries; June 2013.
Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Massica D. Seeing the big picture in long-term surveillance for rare events. Presented at the North American Association of Central Cancer Registries Annual Conference; 2013.
Midkiff KD, Gilsenan AW, Wu Y, Harris DH, Masica D, Andrews EB. Using cancer registry data to advance the science of drug safety: results from an ongoing postmarketing drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Conference; June 21, 2011. Lexington, KY.
Gilsenan AW, Midkiff KD, Harris DH. Opportunities for improving the use of cancer registry data in drug safety studies: factors influencing interview response rate. Presented at the North American Association of Central Cancer Registries Annual Conference; 2011.
Midkiff KD, Gilsenan AW, Martin RD, Andrews EB, Wu Y, Masica D. The new world in cancer surveillance: accommodating patient privacy and drug safety studies. Presented at the NAACCR; June 2009.
Midkiff KD, Martin RD, Gilsenan AW, Masica D, Andrews EB. New directions in using cancer registry data 5–year results from a patient drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.
Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica N, Andrews EB. Characteristics of patients in a post marketing osteosarcoma surveillance study. Presented at the 34th Meeting of the Scandinavian Sarcoma Group; May 2009.
Martin RD, Gilsenan AW, Wu Y, Midkiff KD, Masica DN. Long-term post-marketing studies: flexibility, perseverance and patience. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.
Martin RD, Gilsenan AW, Midkiff KD, Wu Y, Andrews EB, Masica DN. Adult osteosarcoma surveillance study: results from a telephone survey with patients identified through central cancer registries. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.
Midkiff KD. Webcasting training for the integrated data entry and administration system. Presented at the National Lung Screening Trial Data Management Consortium; February 2004.